5-amino-2-hydroxypyridine | 33630-94-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-amino-2-hydroxypyridine
• 英文别名: 5-aminopyridin-2-ol；2-hydroxy-5-amino pyridine；5-amino-1H-pyridin-2-one
• CAS: 33630-94-3
• 化学式: C₅H₆N₂O
• mdl: MFCD03427652
• 分子量: 110.115
• InChiKey: GDOIKKMNCIMDAO-UHFFFAOYSA-N

物化性质

• 熔点：
  ca 180℃
• 沸点：
  206.4°C (rough estimate)
• 密度：
  1.208

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn,Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• WGK Germany：
  2
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  refrigerated.

SDS

Name:	5-Amino-2-Pyridinol Material Safety Data Sheet
Synonym:	None Known
CAS:	33630-94-3

Section 1 - Chemical Product MSDS Name:5-Amino-2-Pyridinol Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
33630-94-3	5-Amino-2-Pyridinol	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 33630-94-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H6N2O
Molecular Weight: 110

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 33630-94-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Amino-2-Pyridinol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 33630-94-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 33630-94-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 33630-94-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-amino-2-hydroxypyridine 在 盐酸 、 氢氧化钾 、 乙醛 作用下， 生成 1,6-dimethyl-1H-[1,5]naphthyridin-2-one
  参考文献：
  名称：

  249. 1：5-萘啶的某些衍生物

  摘要：

  DOI：

  10.1039/jr9490001157
• 作为产物：
  描述：

  2-羟基-5-硝基吡啶 在 一水合肼 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以100%的产率得到5-amino-2-hydroxypyridine
  参考文献：
  名称：

  A metal–organic framework-templated synthesis of γ-Fe₂O₃ nanoparticles encapsulated in porous carbon for efficient and chemoselective hydrogenation of nitro compounds

  摘要：

  金属-有机框架的热解产生了在多孔碳内良好分散的γ-Fe₂O₃纳米颗粒，表现出在温和条件下对多种硝基化合物的加氢反应中优异的催化活性、化学选择性和可循环利用性。

  DOI：

  10.1039/c6cc00011h

文献信息

• MOF-derived Ni-based nanocomposites as robust catalysts for chemoselective hydrogenation of functionalized nitro compounds
  作者：Bo Tang、Wei-Chao Song、En-Cui Yang、Xiao-Jun Zhao

  DOI：10.1039/c6ra26699a

  日期：——

  electron microscopy (TEM), and X-ray photoelectron spectroscopy (XPS) in detail. The resulting Ni@C nanocomposites served as highly efficient and magnetically recyclable catalysts for the hydrogenation of diverse functionalized nitro compounds to the corresponding anilines under relatively milder conditions. The high catalytic performance and the enhanced stability are ascribed to the synergistic effects

  通过对含镍金属-有机骨架进行轻度热解来制备包裹Ni纳米颗粒的多孔石墨碳层（Ni @ C），其结构通过X射线能谱（XRD），N 2表征吸附-解吸，透射电子显微镜（TEM）和X射线光电子能谱（XPS）的详细信息。所得的Ni @ C纳米复合材料可作为高效且可磁循环的催化剂，用于在相对温和的条件下将各种官能化的硝基化合物氢化为相应的苯胺。较高的催化性能和增强的稳定性归因于金属Ni和石墨碳之间的协同效应和电子转移以及独特的封装结构。在MOF衍生的Ni @ C纳米复合材料中取得的成功可能为设计工业应用中对环境无害的催化加氢工艺铺平道路。
• Structure–activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: Pyrrole regioisomers and propionic acid replacement
  作者：Xicheng Sun、Jian Qiu、Sarah A. Strong、Louis S. Green、Jan W.F. Wasley、Dorothy B. Colagiovanni、Sarah C. Mutka、Joan P. Blonder、Adam M. Stout、Jane P. Richards、Lawrence Chun、Gary J. Rosenthal

  DOI：10.1016/j.bmcl.2011.04.086

  日期：2011.6

  those in respiratory, cardiovascular, and gastrointestinal systems. The pyrrole based N6022 was recently identified as a potent, selective, reversible, and efficacious GSNOR inhibitor which is currently undergoing clinical development. We describe here the synthesis and structure–activity relationships (SAR) of novel pyrrole based analogues of N6022 focusing on scaffold modification and propionic acid

  小号-Nitrosoglutathione还原酶（GSNOR）是醇脱氢酶家族（ADH）的成员，其调节的电平小号通过分解代谢-nitrosothiols（SNOS）小号-nitrosoglutathione（GSNO）。GSNO和SNO与许多疾病的发病机制有关，包括呼吸系统，心血管和胃肠系统疾病。基于吡咯的N6022最近被鉴定为有效，选择性，可逆和有效的GSNOR抑制剂，目前正在临床研究中。我们在这里描述了新型的基于吡咯的N6022类似物的合成和结构-活性关系（SAR）专注于支架改性和丙酸替代。我们使用基于结构的方法鉴定了具有吡咯区域异构体作为支架的同等效力和新颖的GSNOR抑制剂。
• TUBULIN INHIBITORS
  申请人：Lin BioScience, LLC

  公开号：US20190169127A1

  公开（公告）日：2019-06-06

  Provided herein are compounds, pharmaceutical compositions, and methods of treatment for various diseases, such as cancer. In one aspect, the method comprises the treatment of brain cancers or metastatic cancers that spread to the brain.

  本文提供了化合物、药物组合物以及治疗各种疾病（如癌症）的方法。在一个方面，该方法包括治疗脑癌或转移至大脑的癌症。
• Substituted Pyrrolidine-2-Carboxamides
  申请人：Ding Qingjie

  公开号：US20100075948A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式的化合物 其中X、Y、R1、R2、R3、R3、R4、R5、R6和R7如本文所述，以及其对映体和药用可接受的盐和酯。这些化合物可用作抗癌药物。
• Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
  申请人：HALLEY Frank

  公开号：US20090082379A1

  公开（公告）日：2009-03-26

  Compounds of formula (I): wherein Ra, Rb, R, X 1 and X 2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

  式(I)的化合物： 其中Ra、Rb、R、X1和X2如所定义，提供了包括所述化合物的药物组合物、制备过程和使用方法。